NEW
YORK, Feb. 27, 2024 /PRNewswire/ -- J.P.
Morgan Life Sciences Private Capital today announced the
addition of David Epstein to its
Healthcare Advisory Board. Mr. Epstein was CEO of Seagen before
closing its sale to Pfizer in December
2023. David previously served as Executive Partner at
Flagship Pioneering as well as CEO of Novartis Pharmaceuticals. His
30 years of industry experience includes drug development, deal
making, venture investing, commercialization, and leadership
experience on a global scale.
Mr. Epstein will now advise the J.P. Morgan Life Sciences
Private Capital team. The team invests in both early and
growth-stage healthcare companies across multiple strategies
aligned to specific market opportunities, with a focus on novel
therapeutics and technologies in several target areas including
Genetic Medicine, Oncology, Neurodegenerative Disease, Rare
Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and
Neuropsychology.
"As we continue on the journey of therapeutic innovation, we are
excited about our ability to bring together some of the industry's
best minds with J.P. Morgan's extensive healthcare ecosystem to
capture compelling investment opportunities," said Stephen Squinto, Chief Investment Officer of
J.P. Morgan Life Sciences Private Capital. "David brings a
diverse set of skills and expertise to the table and we are
thrilled he has agreed to join us in our quest for innovation in
life sciences."
The J.P. Morgan Life Sciences Private Capital team leverages
JPMorgan Chase's scale, resources, data assets and healthcare
expertise and sits within J.P. Morgan Private Capital, a venture
and growth equity investment platform that is part of J.P. Morgan
Asset Management. The platform finances the continued growth of
private companies and taps into significant pre-IPO value creation
opportunities in the consumer and technology, and life sciences
sectors.
J.P. Morgan Life Sciences Private Capital has attracted a group
of Strategic Advisors comprised of some of the life sciences
industry's foremost experts that will help guide the investment
strategy, help to source investment opportunities and provide
operational expertise to J.P. Morgan's portfolio companies. With
the addition of Mr. Epstein, Strategic Advisors include:
- David Epstein – Past
Chief Executive Officer, Seagen Inc.
- Laurie Glimcher, M.D. –
President and CEO, Dana Farber Cancer Institute
- Jeffrey Leiden, M.D., Ph.D. – Executive Chairman, Vertex
Pharmaceuticals
- Frederic Moll, M.D. –
Chief Development Officer, J&J Medical Devices Companies
- Stephen Oesterle, M.D. –
Former Medtronic SVP, Medicine and Technology
Biographies – Strategic Advisors
David Epstein was most
recently chief executive officer of Seagen, a company that
discovers, develops, manufactures, and commercializes targeted
cancer therapeutics with antibody-drug conjugates at its
core. During David's tenure at Seagen, its portfolio of
innovative targeted cancer medicines grew significantly and he
ultimately led the merger of Seagen with Pfizer. David is also
a board member at Valo Health, a company using AI and machine
learning technology to reimagine drug discovery and development.
From 2010-2016, David served as chief executive officer of Novartis
Pharmaceuticals, a division of Novartis AG. Previously, David
started and led Novartis' Oncology and Molecular Diagnostic units.
David's experience also extends to early-stage discovery and
innovation. He served as a consultant to Flagship Pioneering, a
developer of bioplatform companies, Invus and several other firms.
He has served as Chairman at Rubius Therapeutics, Axcella
Therapeutics, Evelo Bio and as a
board member at Ring Therapeutics, Tarus Therapeutics until its
successful sale in June 2022,
Senti Bio, Woosley Pharma and
Cellestia AG. Over the course of his career, he led the development
and commercialization of over 30 new molecular entities, including
major breakthroughs such as Gleevec, Tasigna, Gilenya, Afinitor,
Cosentyx and Entresto. His teams gained approval for over 100 new
indications and launched three Prix
Galien award winning medicines. He was also recognized by
FierceBiotech as one of the "25 most influential people in
biopharma."
Laurie H. Glimcher, M.D.
was named President and CEO of the Dana-Farber Cancer Institute in
2016. She is also Director of the Dana-Farber/Harvard Cancer Center
and the Richard and Susan Smith Professor of Medicine at
Harvard Medical School. Previously, she
was the Stephen and Suzanne Weiss Dean and Professor of Medicine of
Weill Cornell Medicine and Provost for Medical Affairs of
Cornell University. Dr. Glimcher is a
distinguished immunologist, widely renowned for her work in one of
the most promising areas of cancer research. She is a Member of the
National Academy of Sciences, the National Academy of Medicine and
the American Philosophical Society, Fellow of the American Academy
of Arts and Sciences and the former President of the American
Association of Immunologists. She previously served on the Board of
Directors of Bristol-Myers Squibb Pharmaceutical Corporation,
GlaxoSmithKline Pharmaceutical Corporation and the Waters
Corporation. She currently serves on the Board of Directors
of Analog Devices, Inc.
Jeffrey Leiden, M.D, Ph.D., is a physician and scientist
who has dedicated his career to improving the lives of people with
serious diseases. He currently serves as Vertex's Executive
Chairman and was the Chief Executive Officer and President from
2012 through March 2020. He has been
a member of Vertex's board of directors since July 2009, chairman of the board of directors
since May 2012, and served as lead
independent director from October
2010 through December 2011.
Prior to joining Vertex, Dr. Leiden was a managing director at
Clarus Ventures, a life sciences venture capital firm, from 2006
through January 2012. Dr. Leiden was
President, Chief Operating Officer and Chief Scientific Officer of
Abbott Laboratories, Pharmaceuticals Products Group, and a member
of the board of directors of Abbott Laboratories from 2000 to 2006.
He is an elected member of both the American Academy of Arts and
Sciences and the National Academy of Medicine. Dr. Leiden serves as
a director of Massachusetts Mutual Life Insurance Company and as
chairman of Odyssey Therapeutics, a privately held company
developing novel medicines for the treatment of cancer and
autoimmune diseases and Casana Health, a privately held home-health
monitoring company. He is also chairman of the board of Revolution
Healthcare (REVH), a SPAC focused on companies that utilize novel
technologies to revolutionize the treatment and delivery of mental
healthcare. He is also a member of the MIT CEO Advisory Board, a member of the Harvard
Medical School Board of Fellows, and chairman of the Massachusetts
Competitive Partnership (MACP). Dr. Leiden received his M.D., Ph.D.
and B.A. degrees from the University of
Chicago.
Frederic (Fred) Moll, M.D.
is Chief Development Officer of J&J Medical Devices Companies,
having sold his sixth company, Auris Health, Inc., to J&J for
$5.75 billion in 2019. Fred was the
co-founder and CEO of Intuitive Surgical, the world's leading
medical robotics company today, with a market capitalization
exceeding $100 billion. Fred is not
only considered the "Father of Robotic Surgery" (having also
founded Hansen Medical), Fred conceived and commercialized the
early critical products that allowed minimally invasive
laparoscopic surgery to be performed safely with his invention of
the safety shield trocar (Endotherapeutics) and balloon distention
tools (Origin MedSystems). Fred attended the University of California at Berkeley where he
earned a B.A. degree, earned his M.D. degree from the University of Washington and attained an M.S. in
Management from the Stanford Business School.
Stephen Oesterle, M.D.
served as Medtronic's Senior Vice President for Medicine and
Technology, was a member of the Medtronic Executive Committee for
14 years, and currently serves on four public life
sciences/healthcare boards. By forging relationships with global
technology partners and technical universities, he oversaw long
term internal technology investments while participating in
strategic corporate investments in emerging private companies. He
also served as a member of the Business Development and Strategy
Committee that approved all corporate acquisitions. During his
tenure at Medtronic Dr. Oesterle served on more than 20 boards as a
director or observer and built a strong and enduring profile for
Medtronic in the global venture capital and private equity
communities. Prior to joining Medtronic, he was an associate
professor at Harvard Medical School and
practicing interventional cardiologist. Steve earned his bachelor's
degree with Distinction at Harvard
University and his MD at Yale Medical
School.
About J.P. Morgan Global Alternatives & J.P. Morgan
Private Capital
J.P. Morgan Private Capital provides customized financing
solutions for private companies across the capital structure with a
focus on venture and growth investing. The platform's solutions
span the consumer, technology, and life sciences sectors. J.P.
Morgan Private Capital is part of J.P. Morgan Global Alternatives,
the alternative investment arm of J.P. Morgan Asset Management.
With more than 60 years as an alternatives investment
manager, US$213 billion in assets under management and
more than 800 professionals (as of December 31, 2023), J.P.
Morgan offers strategies across the alternative investment spectrum
including real estate, private equity, private credit, hedge funds,
infrastructure, transportation, timber and liquid alternatives.
Operating from offices throughout the
Americas, Europe and Asia Pacific, our independent
alternative investment engines combine specialist knowledge and
singular focus with the global reach, vast resources and powerful
infrastructure of J.P. Morgan to help meet each client's specific
objectives.
About J.P. Morgan Asset Management
J.P. Morgan Asset Management, with assets under management
of $3.1 trillion (as of 12/31/2023), is a global leader
in investment management. J.P. Morgan Asset Management's clients
include institutions, retail investors and high net worth
individuals in every major market throughout the world. J.P. Morgan
Asset Management offers global investment management in equities,
fixed income, real estate, hedge funds, private equity and
liquidity. For more
information: www.jpmorganassetmanagement.com. J.P.
Morgan Asset Management is the marketing name for the asset
management businesses of JPMorgan Chase & Co., and its
affiliates worldwide.
JPMorgan Chase & Co. (NYSE: JPM) is a leading
financial services firm based in the United States of America ("U.S."), with
operations worldwide. JPMorgan Chase had $3.9 trillion in
assets and $328 billion in stockholders' equity as
of December 31, 2023. The Firm is a leader in investment
banking, financial services for consumers and small businesses,
commercial banking, financial transaction processing and asset
management. Under the J.P. Morgan and Chase brands, the Firm serves
millions of customers in the U.S., and many of the world's most
prominent corporate, institutional and government clients globally.
Information about JPMorgan Chase & Co. is available
at www.jpmorganchase.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-team-adds-healthcare-veteran-and-past-seagen-ceo-david-epstein-to-advisory-board-302072726.html
SOURCE J.P. Morgan Asset Management